Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Apr 10, 2016 4:47pm
249 Views
Post# 24749973

RE:zenith

RE:zenith Hi regardless.

I do believe that at some point there will be liquidity, however, as I've posted before, I am extremely frustrated by Don's flippant statements.

A year ago he said there would be an IPO in Q4 2015 and he failed. At the update on Jan 7th he said there will be an IPO in 2016 through a reverse takeover of an already TSX or NASDAQ listed company.

Some have surmised that with the new structure of Zenith into ZEN Capital and ZEN Epigenetics there is the possibility of IPOs for each ZEN Epi drug such as ZEN 3694 if the prostate trial tuns out positive. If that trial shows early success it could sky rocket RVX shares and very quickly lead to a ZEN IPO (IMHO).

If this takes place I believe Zenith will be a gold mine of ongoing IPO's for various indications in cancer, CKD and many concerns re inflammation.

But Don said that Zeniith is a long term strategy (3 years). The 3 years coincides approximately when rvx-208 could start to generate revenue re CVD and DM.

If I live that long I will be a very happy investor with the various ZEN IPOs and the royalty revenues flowing into ZEN Capital.

So I am not much help to you on your question but I'm sure there are many extremely upset Zenith shareholders at this stage...I for one.

My opinion is that they seem to have highly talented scientists working on various projects. So it will be a matter of time.
Cheers
Toinv




Bullboard Posts